Delivery Order SPE2DB22D2005-SPE2DB25FJQG4
- Not listed
- The Defense Logistics Agency awarded a $1,434.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 MCG/2 ML syringes on July 22, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside delivery order represents a pediatric immunoglobulin product sourced through AmerisourceBergen's extensive federal pharmaceutical supply network. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,434.00 delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 MCG/2 ML syringes on September 17, 2025, with an ultimate completion date of October 8, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The delivery is to be performed at AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $3,824.00 delivery order by the Defense Logistics Agency on September 11, 2025, for the supply of Rhophylac 300 micrograms per 2 milliliter syringes. This is a competitively awarded, non-set-aside contract utilizing firm fixed pricing, with an ultimate completion date of October 2, 2025. The award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- This delivery order, valued at $4,302.00, awards AmerisourceBergen Drug Corp the supply of Rhophylac 300 MCG/2 ML syringes under a competitively awarded, firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award was issued on September 15, 2025, with an ultimate completion date of October 6, 2025. Rhophylac is an immunoglobulin product used for prevention of hemolytic disease in newborns and other clinical applications. The contract does not utilize a...
- The Defense Logistics Agency awarded a $1,434.00 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for Rhophylac 300 mcg/2 mL syringes, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,147.20 to AmerisourceBergen Drug Corp for Rhophylac 300 mcg/2 mL syringes on August 29, 2025, with an ultimate completion date of September 22, 2025. This firm fixed price, non-set-aside contract represents a straightforward pharmaceutical procurement executed through AmerisourceBergen's existing indefinite delivery vehicle with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rhophylac 300 mcg/2 mL syringes with a ceiling value of $1,720.80 and a firm fixed price structure. The contract is not set-aside and represents a competitive award to the pharmaceutical distributor. Performance will be completed by October 10, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rhophylac 300 mcg/2 mL syringes, with a ceiling value of $10,755.00. The contract, awarded on July 25, 2025, carries a firm fixed price structure with an ultimate completion date of August 15, 2025. This delivery order does not utilize a set-aside designation and represents a competitive award to the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania....
- This federal contract award is for the delivery of RHOPHYLAC 300 MCG/2 ML SYRINGE 2ML medical supplies to the Defense Logistics Agency (DLA). The $1,836.04 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on August 13, 2024, with a completion date of September 4, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,836.04 firm fixed price contract is for the supply of RHOPHYLAC, a 300 mcg/2 mL syringe medication, with an ultimate completion date of October 15, 2024. The award does not utilize a set-aside designation. AmerisourceBergen holds multiple Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, collectively valued up to...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJQG4Delivery Order
The Defense Logistics Agency awarded a $1,434.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Rhophylac 300 mcg/2 mL syringes on July 23, 2025, with completion targeted for August 13, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rhophylac is a Rho(D) immune globulin used in obstetric and transfusion medicine settings to prevent Rh sensitization. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and the Defense Health Agency. This delivery order exemplifies the company's role in fulfilling federal medical procurement requirements through its global pharmaceutical support vehicle, which enables flexible distribution of specialty medications, vaccines, syringes, and other essential healthcare commodities across multiple therapeutic domains worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/23/25 |